Tekirdağ Namik Kemal University, Faculty of Medicine, Department of Family Physician - Tekirdag, Turkey.
Tekirdağ Namik Kemal University, Faculty of Medicine, Department of Medical Biochemistry - Tekirdag, Turkey.
Rev Assoc Med Bras (1992). 2021 Oct;67(10):1403-1408. doi: 10.1590/1806-9282.20210389.
This study aimed to investigate the seropositivity of CoronaVac-SinoVac vaccination in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) risk factors and comorbidities.
Immunoglobulin (IgG) antibody responses were examined on the 21st day after the second dose of CoronaVac-SinoVac 6 μg vaccine on the 28th day. SARS-CoV-2 IgG antibody levels were measured by using the enzyme-linked immunosorbent assay method in vaccinated health care workers (n=134) (Group I), vaccinated polymerase chain reaction (PCR) (+) who had coronavirus-19 (COVID-19) disease (n=21) (Group II), and unvaccinated PCR (+) (n=28) (Group III) participants. Subgroups were formed in Group I according to the presence of COVID-19 risk factors and comorbidities (diabetes mellitus, cardiovascular disease, and asthma/allergy) and demographic data.
Seropositivity rates were 95.5, 100, and 89.3% for Groups I, II, and III, respectively. IgG antibody levels were found significantly higher in the group between the ages of 20-30 in group I compared to those aged 31-50 and over 50 (both p<0.01). It was found significantly higher in normal-weight individuals than in the overweight and obese group (both p<0.01). IgG antibody levels were found significantly lower in people with cardiovascular disease and diabetes mellitus compared with those who did not (p<0.05 and p<0.001, respectively). There was a negative correlation between IgG antibody response values and body mass index and age in Group I (r= -0.336, p<0.001 and r= -0.307, p<0.001, respectively).
IgG antibody values decrease with age and with increasing body mass index. The presence of comorbidities (i.e., diabetes mellitus and cardiovascular disease) decreased COVID-19 IgG antibody values.
本研究旨在探讨科兴中维新冠疫苗接种者中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）危险因素和合并症的血清阳性率。
在接种科兴中维 6μg 疫苗第 2 剂后第 21 天，采用酶联免疫吸附试验法检测免疫球蛋白（IgG）抗体应答。检测接种疫苗的医护人员（n=134）（第 I 组）、接种聚合酶链反应（PCR）（+）并患有冠状病毒病（COVID-19）（n=21）（第 II 组）和未接种疫苗的 PCR（+）（n=28）（第 III 组）参与者的 SARS-CoV-2 IgG 抗体水平。根据 COVID-19 危险因素和合并症（糖尿病、心血管疾病和哮喘/过敏）和人口统计学数据，在第 I 组中形成亚组。
第 I、II 和 III 组的血清阳性率分别为 95.5%、100%和 89.3%。第 I 组中 20-30 岁年龄组的 IgG 抗体水平明显高于 31-50 岁和 50 岁以上年龄组（均 p<0.01）。正常体重者明显高于超重和肥胖组（均 p<0.01）。与无心血管疾病和糖尿病的参与者相比，患有心血管疾病和糖尿病的参与者的 IgG 抗体水平明显较低（分别为 p<0.05 和 p<0.001）。第 I 组中 IgG 抗体反应值与体重指数和年龄呈负相关（r=-0.336，p<0.001 和 r=-0.307，p<0.001）。
IgG 抗体值随年龄和体重指数的增加而降低。合并症（即糖尿病和心血管疾病）的存在降低了 COVID-19 IgG 抗体值。
